Alcohol derivatives as kv7 potassium channel openers
WO2021023617A1
Alcohol derivatives as kv7 potassium channel openers
WO2021023616A1
Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures
WO2021014389A1
Anti-mglur5 antibodies and uses thereof
US2021002292A1
Modulators of the nmda receptor
US2021047342A1
Prodrugs of modulators of the nmda receptor
JP2020152732A
1-[2[(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as compound with combined serotonin reuptake 5-ht3 and 5-ht1a activity for treatment of cognitive impairment
WO2020234274A1
New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234277A1
Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234276A1
New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234275A1
New catecholamine prodrugs for use in the treatment of parkinson's diseases
US2020369706A1
Process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
US2020392176A1
Solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
US2020369615A1
Process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline and (4ar,10ar)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol
US2020369705A1
A process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
WO2020216920A1
N-((heteroaryl)methyl)-1-tosyl-1h-pyrazole-3-carboxamide derivatives as kv3 potassium channel activators for treating neurological and psychiatric disorders
WO2020216919A1
ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS
WO2020193500A1
Use of a ps396 assay to diagnose tauophaties
WO2020157257A1
Injectable carbamazepine composition essentially free of 10-br-carbamazepine
WO2020114853A1
Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
